Corporate News Blog – Insys Therapeutics Releases Statement on Illinois Settlement; Provides Data against the Opioid-Induced Calamity in the US

Research Desk Line-up: La Jolla Pharma Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 24, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=INSY. The Company announced on August 22, 2017, the following statement concerning the settlement with the State of Illinois. The Company stated that like so many stakeholders in the healthcare community and in the government, it shares the desire to address the serious national challenge related to the misuse and abuse of opioids that has led to addiction and unnecessary deaths and has caused pain to families and communities around the country. This case follows the August 25, 2016, ruling where Illinois attorney general, Lisa Madigan, sued Insys Therapeutics, accusing it of deceptively marketing and selling an addictive fentanyl-based medication, intended to treat cancer pain to doctors for off-label uses. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected La Jolla Pharmaceutical Company (NASDAQ: LJPC) for due-diligence and potential coverage as the Company reported on July 27, 2017, its financial results for the three and six months which ended on June 30, 2017, and also reported recent corporate progress. Tune in to our site to register for a free membership, and be among the early birds that get our report on La Jolla Pharma when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on INSY; also brushing on LJPC. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=INSY

http://protraderdaily.com/optin/?symbol=LJPC

The Lawsuit

The lawsuit filed by Lisa Madigan in Cook County Circuit Court followed a number of state and investigations involving Insys’ drug Subsys as US authorities seek to combat a national opioid abuse epidemic. Subsys, which Insys launched in 2012, is a spray approved for managing pain in cancer patients that contain fentanyl, a highly-addictive regulated synthetic opioid, which generated $329.5 million in net revenue in 2015. The lawsuit alleged that rather than marketing the drug to oncologists to treat cancer patients, Insys instead illegally marketed it to doctors who prescribed high volumes of opioid drugs. The case came to light after federal prosecutors in Manhattan in June 2016, brought charges against two former Insys’ employees for engaging in a scheme to pay doctors kickbacks including speaker fees to prescribe Subsys.

The case rose amid a series of investigations centered on Subsys, an under-the-tongue spray intended for cancer patients that contains fentanyl. Back in December, the investigations led to Boston federal prosecutors charging six former Insys’ executives and managers, including former Chief Executive Michael Babich, with engaging in a scheme to bribe doctors to prescribe Subsys.

The Announcement

Insys stated that the recent settlement with the State of Illinois, which included an obligation to make a $4.45 million payment, reflected the Company’s commitment to take responsibility for actions by the former employees, and affirmed its intent to putpatient first. The Company does not believe it is factually accurate to state that Insys materially contributed to the opioid crisis in the State of Illinois or the nation. The Company made available a large amount of data and other fact to solidify its stance on the opioid crisis. The Company set forth below some of the relevant facts for consideration regarding the product:

By many estimates, the crisis began more than 15 years ago, while Subsys has been available since March 2012.

In 2016, Subsys accounted for about 34,000 prescriptions nationally and less than 1,000 prescriptions in the State of Illinois. In other words, in 2016, Subsys was less than 0.02% of all opioid prescriptions nationally and less than 0.01% of all opioid prescriptions in the State of Illinois.

The 2016 prescription numbers for Subsys do not place Insys within the bracket of top 50 opioid manufacturers in the United States.

According to Insys, a doctor is not permitted to prescribe, a pharmacy is not permitted to dispense, and a patient is not permitted to receive any TIRF product, including Subsys, unless each one of them is enrolled in the FDA mandatory Risk Evaluation and Mitigation strategy program.

Last Close Stock Review

On Wednesday, August 23, 2017, Insys Therapeutics’ stock closed the trading session at $9.07, marginally up 0.22% from its previous closing price of $9.05. A total volume of 270.15 thousand shares were exchanged during the session. The stock currently has a market cap of $667.28 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 473620